Planned and ongoing studies on Pulmonary Hypertension in Switzerland
For further information please contact the investigators.
Bosentan in PAH-patients with Eisenmenger's disease.
Further information: Prof. Maurice Beghetti, HUG Genève, email@example.com
Assessment of PAH by an improved 6-minute-walk-test and mobile ergospirometry; test conditions with or without bosentan.
Further information: Prof. Michael Tamm, Dept. of Pneumology, University Hospital Basle, firstname.lastname@example.org
Serotonin-Reuptake-Inhibitors in PH
Study on the effect of additive fluoxetine in PAH and the prevalence of depression and 5-HHT LL polymorphism.
Further information: Dr. Silvia Ulrich, University Hospital Zürich, Dept. of Internal Medicine, email@example.com
These studies are currently including patients in Zurich
Contact for all: firstname.lastname@example.org
Effect of long-term oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension.
Effect of short-term ambulatory oxygen therapy on cardiopulmonary exercise capacity in patients with precapillary pulmonary hypertension
Noninvasive determination of cerebral tissue oxygenation and cerebral blood flow with Near-Infrared Spectroscopy
in patients with pulmonary hypertension undergoing right heart catheterization
Patients with chronic pulmonary disease at altitude
Riociguat in PH-IIP: A Randomized, Double-Blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg TID) in Patients with Symptomatic Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias (IIP).
MERIT-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension.
Respite: An open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to treatment with approved dosages of phosphodiesterase-5 inhibitors (PDE-5i)